MicroRNA-744 promotes carcinogenesis in osteosarcoma through targeting LATS2

Sun,Liangzhi; Liu,Ming; Luan,Suxian; Shi,Yulin; Wang,Qiang

doi:10.3892/ol.2019.10530

MicroRNA-744 promotes carcinogenesis in osteosarcoma through targeting LATS2

Authors:
- Liangzhi Sun
- Ming Liu
- Suxian Luan
- Yulin Shi
- Qiang Wang
View Affiliations

Affiliations: Department of Orthopedics, Weifang People's Hospital, Weifang, Shandong 261041, P.R. China, Department of Orthopedics, Hanting People's Hospital, Weifang, Shandong 261100, P.R. China, Reproductive Medicine Centre, Weifang People's Hospital, Weifang, Shandong 261041, P.R. China
Published online on: June 26, 2019 https://doi.org/10.3892/ol.2019.10530
Pages: 2523-2529
Copyright: © Sun et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Osteosarcoma (OS) mortality rate is increasing. Various microRNAs (miRNAs) have been investigated in the pathological process of OS except for miR-744. Hence, this research was designed to explore miR-744 function in OS. RT-qPCR and western blot analysis were used to quantify miR-744 and large tumor suppressor kinase 2 (LATS2) expression levels. The function of miR-744 was investigated using MTT and Transwell assays. Target gene of miR-744 was verified by dual-luciferase reporter assay. miR-744 expression was increased in OS, which was associated with worse clinical features and prognosis of OS patients. Importantly, miR-744 promoted cell viability and metastasis in OS. Furthermore, miR-744 induced Wnt/β-catenin pathway and epithelial‑mesenchymal transition (EMT) in OS. In addition, miR-744 directly targeted LATS2 and blocked its expression in OS. Moreover, upregulation of LATS2 weakened the promotion of cell viability and metastasis induced by miR-744 in OS. In conclusion, miR-744 accelerated OS progression through restraining LATS2 and activating Wnt/β‑catenin pathway and EMT.

View Figures

View References

1	Clark JC, Dass CR and Choong PF: A review of clinical and molecular prognostic factors in osteosarcoma. J Cancer Res Clin Oncol. 134:281–297. 2008. View Article : Google Scholar : PubMed/NCBI
2	Geller DS and Gorlick R: Osteosarcoma: A review of diagnosis, management, and treatment strategies. Clin Adv Hematol Oncol. 8:705–718. 2010.PubMed/NCBI
3	Cortini M, Avnet S and Baldini N: Mesenchymal stroma: Role in osteosarcoma progression. Cancer Lett. 405:90–99. 2017. View Article : Google Scholar : PubMed/NCBI
4	Tsiambas E, Fotiades PP, Sioka C, Kotrotsios D, Gkika E, Fotopoulos A, Mastronikolis SN, Armata IE, Giotakis E and Ragos V: Novel molecular and metabolic aspects in osteosarcoma. J BUON. 22:1595–1598. 2017.PubMed/NCBI
5	Zhou L, Ma X, Yue J, Chen T, Wang XY, Wang ZW, Pan J and Lin Y: The diagnostic effect of serum miR-139-5p as an indicator in osteosarcoma. Cancer Biomark. 23:561–567. 2018. View Article : Google Scholar : PubMed/NCBI
6	Chen Z, Zhao G, Zhang Y, Ma Y, Ding Y and Xu N: MiR-199b-5p promotes malignant progression of osteosarcoma by regulating HER2. J BUON. 23:1816–1824. 2018.PubMed/NCBI
7	Liu JL, Li J, Xu JJ, Xiao F, Cui PL, Qiao ZG, Chen XD, Tao WD and Zhang XL: MiR-144 inhibits tumor growth and metastasis in osteosarcoma via dual-suppressing RhoA/ROCK1 signaling pathway. Mol Pharmacol. 95:451–461. 2019. View Article : Google Scholar : PubMed/NCBI
8	Deng Y, Li Y, Fang Q, Luo H and Zhu G: microRNA-744 is downregulated in glioblastoma and inhibits the aggressive behaviors by directly targeting NOB1. Am J Cancer Res. 8:2238–2253. 2018.PubMed/NCBI
9	Zhou W, Li Y, Gou S, Xiong J, Wu H, Wang C, Yan H and Liu T: MiR-744 increases tumorigenicity of pancreatic cancer by activating Wnt/β-catenin pathway. Oncotarget. 6:37557–37569. 2015. View Article : Google Scholar : PubMed/NCBI
10	Tan YL, Bai ZG, Zou WL, Ma XM, Wang TT, Guo W, Liu J, Li JS, Jie-Yin, Zang YJ, et al: miR-744 is a potential prognostic marker in patients with hepatocellular carcinoma. Clin Res Hepatol Gastroenterol. 39:359–365. 2015. View Article : Google Scholar : PubMed/NCBI
11	Zhang Y, Hu CF, Chen J, Yan LX, Zeng YX and Shao JY: LATS2 is de-methylated and overexpressed in nasopharyngeal carcinoma and predicts poor prognosis. BMC Cancer. 10:5382010. View Article : Google Scholar : PubMed/NCBI
12	Li Y, Pei J, Xia H, Ke H, Wang H and Tao W: Lats2, a putative tumor suppressor, inhibits G1/S transition. Oncogene. 22:4398–4405. 2003. View Article : Google Scholar : PubMed/NCBI
13	Ke H, Pei J, Ni Z, Xia H, Qi H, Woods T, Kelekar A and Tao W: Putative tumor suppressor Lats2 induces apoptosis through downregulation of Bcl-2 and Bcl-x(L). Exp Cell Res. 298:329–338. 2004. View Article : Google Scholar : PubMed/NCBI
14	Dai X, She P, Chi F, Feng Y, Liu H, Jin D, Zhao Y, Guo X, Jiang D, Guan KL, et al: Phosphorylation of angiomotin by Lats1/2 kinases inhibits F-actin binding, cell migration, and angiogenesis. J Biol Chem. 288:34041–34051. 2013. View Article : Google Scholar : PubMed/NCBI
15	Lee KH, Goan YG, Hsiao M, Lee CH, Jian SH, Lin JT, Chen YL and Lu PJ: MicroRNA-373 (miR-373) post-transcriptionally regulates large tumor suppressor, homolog 2 (LATS2) and stimulates proliferation in human esophageal cancer. Exp Cell Res. 315:2529–2538. 2009. View Article : Google Scholar : PubMed/NCBI
16	Han LL, Yin XR and Zhang SQ: miR-103 promotes the metastasis and EMT of hepatocellular carcinoma by directly inhibiting LATS2. Int J Oncol. 53:2433–2444. 2018.PubMed/NCBI
17	Livak KJ and Scmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
18	Cai H, Miao M and Wang Z: miR-214-3p promotes the proliferation, migration and invasion of osteosarcoma cells by targeting CADM1. Oncol Lett. 16:2620–2628. 2018.PubMed/NCBI
19	Li W, Meng Z, Zou T, Wang G, Su Y, Yao S and Sun X: MiR-374a activates Wnt/β-catenin signaling to promote osteosarcoma cell migration by targeting WIF-1. Pathol Oncol Res. Dec 6–2018.(Epub ahead of print). View Article : Google Scholar
20	Yu Q, Zhang F, Du Z and Xiang Y: Up-regulation of serum miR-744 predicts poor prognosis in patients with nasopharyngeal carcinoma. Int J Clin Exp Med. 8:13296–13302. 2015.PubMed/NCBI
21	Miyamae M, Komatsu S, Ichikawa D, Kawaguchi T, Hirajima S, Okajima W, Ohashi T, Imamura T, Konishi H, Shiozaki A, et al: Plasma microRNA profiles: Identification of miR-744 as a novel diagnostic and prognostic biomarker in pancreatic cancer. Br J Cancer. 113:1467–1476. 2015. View Article : Google Scholar : PubMed/NCBI
22	Li C, Jia L, Yu Y and Jin L: Lactic acid induced microRNA-744 enhances motility of SiHa cervical cancer cells through targeting ARHGAP5. Chem Biol Interact. 298:86–95. 2019. View Article : Google Scholar : PubMed/NCBI
23	Zhang M and Li H, Zhang Y and Li H: Oncogenic miR-744 promotes prostate cancer growth through direct targeting of LKB1. Oncol Lett. 17:2257–2265. 2019.PubMed/NCBI
24	Guan H, Liu C, Fang F, Huang Y, Tao T, Ling Z, You Z, Han X, Chen S, Xu B, et al: MicroRNA-744 promotes prostate cancer progression through aberrantly activating Wnt/β-catenin signaling. Oncotarget. 8:14693–14707. 2017. View Article : Google Scholar : PubMed/NCBI
25	Wang C, Zong J, Li Y, Wang X, Du W and Li L: MiR-744-3p regulates keratinocyte proliferation and differentiation via targeting KLLN in psoriasis. Exp Dermatol. 28:283–291. 2019. View Article : Google Scholar : PubMed/NCBI
26	Vislovukh A, Kratassiouk G, Porto E, Gralievska N, Beldiman C, Pinna G, El'skaya A, Harel-Bellan A, Negrutskii B and Groisman I: Proto-oncogenic isoform A2 of eukaryotic translation elongation factor eEF1 is a target of miR-663 and miR-744. Br J Cancer. 108:2304–2311. 2013. View Article : Google Scholar : PubMed/NCBI
27	Fang L, Du WW, Yang W, Rutnam ZJ, Peng C, Li H, O'Malley YQ, Askeland RW, Sugg S, Liu M, et al: MiR-93 enhances angiogenesis and metastasis by targeting LATS2. Cell Cycle. 11:4352–4365. 2012. View Article : Google Scholar : PubMed/NCBI
28	Cho WJ, Shin JM, Kim JS, Lee MR, Hong KS, Lee JH, Koo KH, Park JW and Kim KS: miR-372 regulates cell cycle and apoptosis of ags human gastric cancer cell line through direct regulation of LATS2. Mol Cells. 28:521–527. 2009. View Article : Google Scholar : PubMed/NCBI
29	Zheng YB, Xiao K, Xiao GC, Tong SL, Ding Y, Wang QS, Li SB and Hao ZN: MicroRNA-103 promotes tumor growth and metastasis in colorectal cancer by directly targeting LATS2. Oncol Lett. 12:2194–2200. 2016. View Article : Google Scholar : PubMed/NCBI
30	Gao Y, Yi J, Zhang K, Bai F, Feng B, Wang R, Chu X, Chen L and Song H: Downregulation of MiR-31 stimulates expression of LATS2 via the hippo pathway and promotes epithelial-mesenchymal transition in esophageal squamous cell carcinoma. J Exp Clin Cancer Res. 36:1612017. View Article : Google Scholar : PubMed/NCBI
31	Feng S, Pan W, Jin Y and Zheng J: MiR-25 promotes ovarian cancer proliferation and motility by targeting LATS2. Tumour Biol. 35:12339–12344. 2014. View Article : Google Scholar : PubMed/NCBI
32	Han LL, Yin XR and Zhang SQ: miR-650 promotes the metastasis and epithelial-mesenchymal transition of hepatocellular carcinoma by directly inhibiting LATS2 expression. Cell Physiol Biochem. 51:1179–1192. 2018. View Article : Google Scholar : PubMed/NCBI